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AbsTrACT
visual hallucinations are common in older people 
and are especially associated with ophthalmological 
and neurological disorders, including dementia and 
Parkinson’s disease. Uncertainties remain whether there 
is a single underlying mechanism for visual hallucinations 
or they have different disease- dependent causes. 
However, irrespective of mechanism, visual hallucinations 
are difficult to treat. The National institute for Health 
Research (NiHR) funded a research programme to 
investigate visual hallucinations in the key and high 
burden areas of eye disease, dementia and Parkinson’s 
disease, culminating in a workshop to develop a unified 
framework for their clinical management. Here we 
summarise the evidence base, current practice and 
consensus guidelines that emerged from the workshop.
irrespective of clinical condition, case ascertainment 
strategies are required to overcome reporting stigma. 
Once hallucinations are identified, physical, cognitive 
and ophthalmological health should be reviewed, 
with education and self- help techniques provided. 
Not all hallucinations require intervention but for 
those that are clinically significant, current evidence 
supports pharmacological modification of cholinergic, 
GABAergic, serotonergic or dopaminergic systems, or 
reduction of cortical excitability. A broad treatment 
perspective is needed, including carer support. Despite 
their frequency and clinical significance, there is a 
paucity of randomised, placebo- controlled clinical 
trial evidence where the primary outcome is an 
improvement in visual hallucinations. Key areas for 
future research include the development of valid and 
reliable assessment tools for use in mechanistic studies 
and clinical trials, transdiagnostic studies of shared and 
distinct mechanisms and when and how to treat visual 
hallucinations.
INTroduCTIoN
Visual hallucinations (VH) and closely- related 
visual perceptual symptoms (box 1) are common 
in degenerative diseases of the brain and eye, and 
their prevalence varies depending on the condition 
and symptom type. The three predominant clinical 
contexts in which VH occur as repeated episodes 
over a prolonged course are the (i) dementias, (ii) 
Parkinson’s disease (PD), both in its early stages 
and after progression to PD dementia (PDD) and 
(iii) eye or visual pathway disease. Prevalence varies 
across different dementia subtypes with recent 
estimates of 55% to 78% in dementia with Lewy 
bodies (DLB), 32% to 63% in PDD, 11% to 17% in 
Alzheimer’s disease (AD) and 5% to 14% in vascular 
dementia.1 In DLB, well- formed and detailed VH 
are a core feature and incorporated into diagnostic 
criteria.2 The term Charles Bonnet syndrome is 
used to describe VH in visual impairment due to 
eye or visual pathway disease, with prevalence 
ranging from 15% to 60% depending on the degree 
of visual loss.3 In PD, prevalence of VH is linked to 
disease duration and dopamine medication, with a 
more than 80% cumulative prevalence over time.4
To date, research into the mechanism and 
treatment of VH has focussed predominantly on 
these three clinical contexts, with the emergence 
of parallel, often contradictory, literature. Little 
consideration has been given to factors common to 
each condition or how mechanisms might interact 
when eye disease combines with dementia or PD. 
The National Institute for Health Research (NIHR) 
funded a 5 year research programme (SHAPED: 
Study of visual Hallucinations in Parkinson’s 
disease, Eye disease and Dementia) to examine VH 
from a transdiagnostic perspective focussing on 
these conditions and to develop a unified frame-
work for clinical management based on combined 
current best practice and treatment evidence. As 
part of this programme, we undertook an expert- led 
review process of recent literature and current prac-
tice, culminating in a workshop held in April 2018 
to formulate consensus guidelines for the clinical 
management of VH.
The underlying mechanism of visual 
hallucinations
The workgroup highlighted two related but distinct 
aspects of VH mechanism that might inform treat-
ment. One was what brain changes occur at the 
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box 1 Glossary of terms
 ► Visual hallucination – visual percept not associated with a 
real object.
 ► Complex visual hallucination – subtype of visual hallucination 
whose content is a formed object, face, animal, figure, etc.
 ► Visual illusion – real object perceived incorrectly. Traditionally 
used to refer to errors of category identity (eg, pile of cloths 
seen as a cat).
 ► Pareidolia – specific subtype of illusion in which faces, 
objects, etc, are perceived when viewing formless visual 
stimuli such as clouds, tree- bark, flames or in patterned visual 
stimuli such as carpets, wallpaper.
 ► Metamorphopsia – a subtype of illusion used to refer to 
errors of spatial, temporal perception (eg, seeing a real object 
distorted, seeing a real object persist in time or at the wrong 
spatial location).
 ► Passage hallucination – animal or person passing (en 
passage), typically brief and in peripheral visual field. 
Characteristic of Parkinson’s disease psychosis.
 ► Presence hallucination – sense of someone being close by 
or beside without an associated visual, auditory or tactile 
experience. Characteristic of Parkinson’s disease psychosis.
 ► Minor hallucination – collective term used in Parkinson’s 
disease to describe illusions, passage hallucinations and 
presence hallucinations.
 ► Multimodality hallucination – visual hallucination combined 
with hallucinations in other senses. Content in different 
modalities may be perceptually related (eg, figure talking 
to you) or perceptually unrelated (disembodied voice with 
content unrelated to figure).
 ► Pseudohallucination – in neurological literature, a 
hallucination with insight. In psychiatric literature, a 
hallucination in the mind’s eye rather than externally 
projected and related to imagery.
 ► Full insight – in the context of visual hallucinations, an 
understanding that the experience is not real. Insight may be 
absent on the first occasion a hallucination occurs because 
of its compelling nature but with repeated instances the 
experience is recognised as false.
 ► Partial or fluctuating insight – in the context of visual 
hallucinations, insight is variable and frequently absent at 
the time the hallucination occurs. Insight may be restored in 
retrospect.
 ► Secondary delusion – a false belief related to the visual 
hallucination (eg, people have been let into the house). 
Secondary delusions imply impaired insight.
time of VH (the hallucinating state); the other being what brain 
changes are associated with a susceptibility to VH (the hallu-
cination trait). Studies of the hallucinating state ideally require 
the examination of real- time brain changes coincident with VH. 
Transient activation of the visual association cortex has been 
found in Charles Bonnet syndrome around the time of onset of 
VH,5 while more widespread changes have been found in PD 
with de- activation of the visual association cortex and activa-
tion of the frontal cortex.6 Differences in methodology make 
it difficult to conclude whether this reflects a difference in the 
mechanism underlying the VH state in these disorders.
However, most attention has been on brain changes associated 
with susceptibility to VH. There are three mechanistic models: 
(i) disturbed balances between top- down and bottom- up aspects 
of visual perception, (ii) chronic deafferentation causing hyper-
excitability to the cortical structures involved in vision and (iii) 
misattribution of internal imagery.
The first mechanism, the Perception Attentional Dysfunc-
tion (PAD) model or related variants,7–9 highlights combined 
impairment in distributed perceptual and attentional networks 
leading to disturbed balances between top- down and bottom- up 
processes (or priors and sensory evidence). This has especially 
been implicated in the aetiology of hallucinations in dementia or 
PD and proposes that, in combination with poor visual percep-
tion, continuous perceptual activity is underconstrained by 
impaired attentional focus and that the hallucinatory element 
of a scene is not disconfirmed by discrepant visual input. In 
contrast, the second, deafferentation- hyperexcitability, model 
is believed to underlie Charles Bonnet syndrome, and proposes 
hyperexcitability secondary to chronic functional visual deaf-
ferentation, resulting in increased spontaneous activity within 
the higher visual cortical areas leading to VH.10 The third 
model, derived from psychotic disorders, is similar to PAD in 
its emphasis on unbalanced generative perception but proposes 
that hallucinations, whatever their modality, result from a failure 
to correctly attribute internal events as internal due to failures in 
source monitoring.11
Each model is supported by a range of evidence including: 
cognitive/higher visual function deficits, functional imaging of 
task- related activity, resting state metabolism or blood flow, 
cortical/white matter changes and altered structural and func-
tional connectivity and postmortem neuropathology. The func-
tional and structural changes differ between studies of VH, both 
within a given condition and across conditions, but may all form 
part of a distributed network.12 13 Pathology involving any part 
of the network may result in dysfunction that leads to VH, as 
shown for anatomically distinct lesion sites causing peduncular 
hallucinations13 and VH in PD.14
Postmortem evidence has the complication that changes iden-
tified may have followed the onset of VH and reflect later disease 
progression rather than the primary cause of VH. Nevertheless, 
VH during life in patients with dementia is a strong predictor of 
Lewy body (LB) pathology at autopsy.15 16 In patients with VH 
associated with PD and DLB, LB pathology is found in the amyg-
dala and parahippocampal gyrus,17 superior and lateral frontal 
cortex (Brodmann area 8/9), inferior/lateral temporal cortex 
(Brodmann area 20, 21), inferior parietal cortex (Brodmann area 
39, 40) and cingulate cortex (Brodmann area 24)(regions pooled 
from.18 19)
Unlike patients with VH in the context of PD with dementia, 
patients with VH, PD and relative preservation of cognition 
do not have prominent cortical or hippocampal LB involve-
ment.20 VH are also linked to higher amyloid and tau pathology 
in frontal, parietal and hippocampal areas,21 and patients with 
PD who go on to develop VH have cerebrospinal fluid (CSF) 
amyloid changes that suggest early AD pathology.22 In PD without 
dementia, the occipital lobe is relatively free of pathology with 
absent LB and tau pathology and mild amyloid burden irrespec-
tive of whether patients experience VH.23
Neurotransmitter systems and VH
In both AD and DLB, there is strong evidence for reduced 
cholinergic function associated with more frequent VH.24–27 
This is consistent with evidence from case series in PD and 
PDD suggesting improvement in VH with cholinesterase inhibi-
tors28–30 and improvement in VH, among other neuropsychiatric 
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symptoms, in the secondary analysis of a large- scale clinical trial 
examining the effect of cholinesterase inhibitors on cognition.31
Neurochemical studies of CSF metabolites suggest a nega-
tive correlation between the dopamine metabolite homovan-
illic acid (HVA) and VH in a small number of LBD patients 
and weak negative correlations with aspartate and taurine in 
AD.32 One suggestion is that VH susceptibility is linked to a 
specific 3,4- dihydro- xyphenylacetic acid- HVA metabolic deficit, 
possibly as a result of a common polymorphism in the catechol- 
O- methyltransferase (COMT) gene. There is also evidence of 
reduced striatal dopamine transporter binding in patients with 
PD who go on to develop VH, thought to reflect dysfunctional 
frontostriatal circuitry and altered inhibitory executive func-
tion33–36 consistent with the PAD model. This may also help 
explain why VH in some patients with PD/PDD improve when 
their dopaminergic load is dropped or partially blocked with 
drugs such as clozapine or quetiapine.
Postmortem studies also highlight reductions in cholinergic 
and GABA activity in the absence of major neuronal or synaptic 
loss, suggesting functional rather than structural changes may 
contribute to VH.37 In PD, increased 5HT2a binding has been 
linked to VH in postmortem38 and in vivo neurotransmitter 
binding studies.39 This may also help explain why the 5HT2a 
inverse agonist pimavanserin is effective treatment for halluci-
nations in PD.
In summary, research on the mechanism of VH has largely 
been confined to studies within a given clinical condition, with 
a paucity of transdiagnostic research on the wider applicability 
of mechanisms or interactions between them. It also remains 
unclear whether mechanisms proposed for complex VH also 
apply to related perceptual symptoms (eg, illusions, presence 
hallucinations), or phenomenological variants of complex VH 
with full, partial/fluctuating and absent insight.
VIsuAl HAlluCINATIoNs ANd THeIr mANAGemeNT
eye disease
Charles Bonnet syndrome VH are associated with diseases 
affecting the retina, light transmission within the eye (eg, cata-
ract, corneal opacity) or visual pathways and visual cortex. 
They do not relate to a specific ocular pathology subtype40 
and can occur in monocular disease. Typical phenomenology 
includes simple hallucinations (colours and elementary shapes) 
geometrical patterns, disembodied faces and costumed figures.41 
Charles Bonnet syndrome risk increases in patients with severe 
impairment of visual acuity.3 The frequency of VH occurrence in 
Charles Bonnet syndrome reduces over time, but more than 75% 
of patients will continue to experience hallucinations beyond 
5 years after their onset.42 Clinical impression, supported by 
patient surveys43 is that Charles Bonnet syndrome is under- 
recognised with the fear of stigma reducing self- report. Around 
a third of Charles Bonnet syndrome patients have symptoms 
requiring clinical intervention beyond reassurance and education 
(negative outcome Charles Bonnet syndrome).42 Compared with 
patients with eye disease but no VH, Charles Bonnet syndrome 
adversely affects quality of life.44
Current practice
For Charles Bonnet syndrome, ophthalmology services will 
explain symptoms, reassure and signpost for further support and 
self- help techniques, with limited evidence from a case series that 
this may reduce VH in some people.45 The self- help techniques 
aim to stop hallucinations at the time they occur and include eye- 
movements, changing lighting levels to increase visual input and 
alerting/distraction strategies. If clinically significant through 
causing distress, referral to other specialities may occur. A staged 
approach to treatment is used with a health screen and medica-
tion review and optimisation of vision (eg, cataract removal).46 
For people with VH associated with acute visual loss due to 
macular degeneration, a study of ranibizumab found improve-
ment in 23%, with an association with improved visual acuity.47 
There is case- report evidence for treatment with anticonvul-
sants,48 49 cholinesterase inhibitors,50 5HT antagonists (ondan-
setron),51 selective serotonin reuptake inhibitors,52 atypical 
neuroleptics,53 Yi- Gan San (a Chinese traditional medicine with 
multiple neurotransmitter effects)54 and repetitive transcranial 
magnetic stimulation.55 However, none can be recommended for 
routine clinical use without further evidence for their efficacy.
Parkinson’s disease
VH in PD form part of a progressive spectrum of symptoms 
(PD psychosis) that start with illusions, presence hallucinations 
and passage hallucinations and progress to formed hallucina-
tions, typically of people and animals.56 They are a particular 
challenge in PD, as treatment for motor symptoms can trigger 
and worsen VH. They are associated with higher mortality,57 
which may be linked to antipsychotic use,58 and are a stronger 
predictor of nursing home placement than cognitive or motor 
symptoms.59 The stigma of mental illness may lead to under- 
reporting.60 VH in PD have a significant negative impact on 
carers, with increasing carer distress as insight into the VH 
becomes impaired.60 Compared with PD patients without VH, 
patients with VH have reduced quality of life.61
Current practice
The NICE (National Institute for Health and Care Excellence) 
2017 guidelines for PD62 recommend a staged approach to treat-
ment, typically undertaken within a PD service. The starting 
point is a review of medical or pharmacological triggers and a 
delirium screen with advice on general coping strategies.63 64 A 
reduction in PD medication may be necessary while monitoring 
for worsening motor symptoms, dopamine withdrawal syndrome 
or neuroleptic malignant syndrome. Medications should be 
withdrawn, starting with those most likely to provoke VH, that 
is, anticholinergics, amantadine and MAO- B inhibitors, followed 
by dopamine agonists and COMT inhibitors. If VH persist, the 
cautious withdrawal of levodopa may help.65 66 If these strate-
gies are not effective, antipsychotic medications may be consid-
ered.67 Several randomised controlled trials (RCTs) have shown 
clozapine to be efficacious, with benefit for VH without wors-
ening motor symptoms.68 69 Quetiapine is more widely used than 
clozapine, but there is less evidence of efficacy.70–73 Pimavan-
serin, a novel antipsychotic with potent inverse agonist activity 
on the 5HT2A receptor, has emerged as a new potential therapy, 
with two positive RCTs. Meltzer et al74 reported reduced VH, 
and Cummings et al75 reported improvements on psychosis 
scores and caregiver stress. Pimavanserin is licensed as a treat-
ment for PD psychosis in the USA. Rivastigmine and donepezil 
are used to treat cognitive impairment in PD and may also help 
reduce VH,28–30 although to date there are no RCTs of cholines-
terase inhibitors using VH as a primary endpoint.
dementia
VH in dementia tend to be of people/children, animals or 
objects.76 Around 50% of patients are significantly distressed by 
their experiences, with fear and anger being the most common 
responses.77 As core defining features of DLB, they are likely to 
 o
n
 April 6, 2020 by guest. Protected by copyright.
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-322702 on 25 March 2020. Downloaded from 
4 O'Brien J, et al. J Neurol Neurosurg Psychiatry 2020;0:1–8. doi:10.1136/jnnp-2019-322702
Neurodegeneration
Table 1 Visual hallucinations in wider clinical and non- clinical 
context
Condition Key features
Parkinson’s disease Occurs throughout PD from early stage disease without cognitive 
impairment to PDD (see above). Other hallucination modalities can be 
involved in later stages.
Charles Bonnet 
syndrome
Eye or visual pathway disease (see above).
Dementia Includes AD, DLB, PDD, AD, VaD (see above). Other hallucination 
modalities can be involved.
Comorbid disease Eye and neurodegenerative disease combined (see above).
Schizophrenia/
bipolar disorder
Visual hallucinations are less prevalent than auditory hallucinations in 
schizophrenia and other psychoses. VH in these conditions rarely occur 
without auditory hallucinations during the course of the illness and 
are typically interspersed with unimodal auditory hallucinations.
Bereavement VH of the deceased can occur as part of normal grief reaction but are 
less frequent than sensed presence of the deceased.
Delirium VH are the most common modality of hallucination in delirium 
where they occur in the context of clouded consciousness, sleep 
dysregulation and affective symptoms.
Sleep- related Occasional VH can be normal experiences at the margins of sleep 
(hypnagogic/hypnopompic hallucinations). They may also present as 
part of a sleep- disorder (eg, narcolepsy).
Medication side 
effects
PD medication can precipitate VH but the exact mechanism and its 
relation to PD neurodegeneration is unclear. Medication with anti- 
muscarinic effects and opiates are particularly implicated in VH.
Hallucinogen use Visual perceptual phenomena including visual snow (see below) 
afterimages, palinopsia and flashback VH may persist after 
hallucinogen exposure (hallucinogen persisting perception disorder).
Peduncular 
hallucinations
Complex visual hallucinations caused by brainstem or thalamic 
lesions. When caused by brainstem lesions, VH are associated with 
sleep disturbance and eye movement dysfunction. Hallucinations in 
other modalities can occur.
Occipital/temporal 
seizures
Ictal phenomenology is based on location of seizure. Simple VH are 
associated with occipital foci. Complex VH imply involvement of the 
temporal lobe and limbic cortex.
Migraine Teichopsia in classical migraine aura and other visual perceptual 
phenomena.
Visual snow 
syndrome
A syndrome characterised by persistent dynamic visual noise (snow), 
palinopsia, entopic phenomena, photophobia and nyctalopia. 
Associated with migraine.
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; PD, Parkinson’s disease; PDD, 
Parkinson’s disease dementia; VaD, vascular dementia; VH, visual hallucinations.
be present at the point of diagnosis, contrasting with AD where 
VH occur in later stages of cognitive decline, 5 to 6 years after 
the onset of dementia.78 VH are associated with increased like-
lihood of nursing home placement.79 As in PD, carer impact 
increases when patient insight becomes impaired.60
Current practice
VH are managed within dementia services in the wider context 
of neuropsychiatric symptoms. A staged approach is used with 
a physical health review, excluding delirium and other medical 
conditions that can cause VH, and medication review to reduce/
stop drugs which may cause or exacerbate VH. Antipsychotics 
may have benefit80 but potential adverse effects of severe anti-
psychotic sensitivity and mortality mean that they should be used 
cautiously in LBD. There is some evidence cholinesterase inhib-
itors reduce neuropsychiatric symptoms, including VH.26 31 81 
High dose cholinesterase inhibitors have been shown to reduce 
the frequency of VH in LBD but with increased side effects, 
needing careful titration under expert supervision.82 A study of 
memantine found reduced hallucinations (which, although not 
subdivided by hallucination modality, would have mainly been 
VH) in DLB after 24 weeks treatment.83 Transcranial magnetic 
stimulation and transcranial direct stimulation have been 
suggested as approaches for VH in LBD, but studies to date have 
not shown benefit.84
Comorbid disease
Studies of VH in PD or dementia typically exclude patients with 
eye disease so there is limited data on the prevalence, phenom-
enology or management of VH in the context of comorbid eye 
disease. Eye disease may result in an earlier onset of VH in 
dementia, resulting in the misdiagnosis of AD as DLB.85 In PD, 
eye disease detectable by general ophthalmological examination 
is not associated with VH;18 86 however, more detailed testing 
with retinal imaging has found reduced retinal nerve fibre layer 
thickness in PD patients with VH.86 Some patients presenting 
with Charles Bonnet syndrome to ophthalmology clinics may 
have unrecognised dementia characterised by partial or fluctu-
ating insight into VH.87 Case report evidence suggests that opti-
mising vision may help reduce VH in dementia.88
dIsCussIoN
The absence of an overarching model for VH in different disor-
ders or evidence- based treatments limited the scope of the recom-
mendations the workgroup could make. The focus of the NIHR 
programme on PD, dementia and eye disease also meant that 
VH in other clinical and non- clinical contexts were not covered 
(schizophrenia/bipolar disorder (s1); bereavement (s2); delirium 
(s3); sleep- related, medication,36 hallucinogen use (s4); pedun-
cular hallucinations (s5); epilepsy (s6 to s7); migraine (s8); visual 
snow syndrome (s9) - see table 1). However, the consensus view 
was that where treatment was indicated for these other condi-
tions, similarities in current practice across the core disorders 
could logically be extended to all conditions. Below we highlight 
key considerations, the general framework for managing VH 
and related symptoms, and areas for future research.
Case identification
Whatever the underlying condition, help can only be provided 
for patients with VH if these symptoms have been identified 
by their clinical team. The workgroup identified the need to 
address continuing stigma of self- reporting symptoms perceived 
as indicators of mental illness or dementia. Evidence from eye 
disease that pre- emptive warning may be effective in reducing 
distress or emotional impact at VH onset42 suggests that low- 
level information about the possible future occurrence of VH 
should be provided at the point of eye disease, dementia or PD 
diagnosis, with signposting to more detailed information which 
can be accessed at a later stage. Systematic enquiry about the 
occurrence of VH should be part of routine follow- up to help 
share responsibility for identifying VH between the patient and 
care team.
Threshold for specific treatment intervention
The workgroup noted that VH that are not distressing for the 
patient or carer do not need treatment beyond general measures, 
psychoeducation and help in adapting, accepting and living well 
with symptoms. Typically, this benign VH phase occurs early in 
the disease, highlighting the importance of keeping VH under 
review. An important factor defining the threshold at which 
intervention is required may be the transition from full insight to 
partial or fluctuating insight, where the patient responds to VH 
as if they are real at the time they occur, even if insight is restored 
after the event. This insight- related phenomenological distinc-
tion corresponds to that in the neurological literature between 
pseudohallucinations (defined by intact insight) and halluci-
nations without insight. The terminology is unsatisfactory as 
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Figure 1 The consensus framework for the management of visual hallucinations in different conditions. Recommendations not supported by meta- analysis 
are indicated in white. Orange boxes indicate hallucination characteristics and therapeutic targets.AD,Alzheimer’s disease; CBS, Charles Bonnet syndrome; 
CBT, cognitive behavioural therapy; DLB, dementia with Lewy bodies;PD, Parkinson’s disease; PDD, PD dementia.
pseudohallucinations carry different implications in the psychi-
atric literature; however, the conceptual distinction between VH 
with insight intact in contrast to partial, fluctuating and absent 
insight states is worth revisiting as it helps mark a transition 
point for treatment need in all conditions. The workgroup also 
noted exceptions to the association between insight and treat-
ment need, for example, intervention might be required in the 
presence of full, continuous insight where VH content is itself 
distressing or VH become so intrusive they limit function.
Carers and VH
Another feature of VH common to different conditions is the 
need to also consider their impact on carers. Factors mediating 
the increased risk of care home placement with VH are unclear 
but may include carer distress caused indirectly by VH. The 
consensus view was that the treatment of VH should extend 
beyond the patient to provide support and advice for the carer.
Consensus framework for the management of VH
The general framework for managing VH and related symp-
toms is summarised in figure 1. It begins before the onset of 
hallucinations with forewarning and pre- emptive questioning 
to encourage their reporting. Once VH are identified, a staged 
approach is suggested with a review of cognitive and ophthalmo-
logical health as well as a physical health/delirium screen. Medi-
cation should be reviewed, focussing on anti- muscarinic and 
opiate drugs and, in PD, dopaminergic therapy. Support including 
reassurance, psychoeducation, normalisation (explaining VH are 
part of a disease and have a basis in brain function) and optimi-
sation of visual functioning should be offered. This should be 
person- centred, identifying the particular triggers and settings 
that increase the risk of VH and avoiding these situations by 
planning alternative meaningful and rewarding activities.
VH that become clinically significant by causing distress to 
the patient or their carers require further intervention. Given 
the current limitations in both our understanding of the under-
lying mechanism(s) of VH susceptibility or the neurophysiolog-
ical changes coincident with VH and the clinical trial evidence 
base, the workgroup were unable to make definitive medication 
recommendations. There is a theoretical basis for pharmacolog-
ical interventions targeting cholinergic, GABAergic, serotonergic 
or dopaminergic systems and for reducing cortical excitability 
through non- invasive stimulation or anticonvulsant medication. 
Treatment might aim to reverse long- term changes associated 
with VH susceptibility or to reduce the frequency or duration of 
transient changes coincident with VH.
Future directions
The working group noted an important methodological chal-
lenge for clinical trials or mechanistic studies is the lack of 
accepted, validated, rating scales for VH or related symptoms. 
There is a clear need to develop better metrics which extend 
beyond retrospective collection of questionnaire or scale data 
to real- world collection of VH as they occur using, for example, 
new mobile technology or real- time functional data through 
developments in electroencephalogram telemetry. Measures 
of VH susceptibility are also required, such as pareidolia tests 
developed for DLB.89 90 Given the importance of insight and its 
continuity at the decision point for specific intervention, better 
measures of insight which are sensitive to partial or fluctuating 
states are required, as well as studies of the cognitive context in 
which insight becomes impaired, for example, generalised cogni-
tive decline or decline in specific cognitive functions such as self- 
monitoring or symptom- awareness.91
For clinical trials, the workgroup highlighted the lack of stan-
dardisation of VH- related outcome measures and the need for 
trials taking a transdiagnostic, mechanism- based perspective to 
complement evidence from the traditional condition- specific 
trials. It remains to be established whether a single treatment 
approach will be effective in all conditions or whether different 
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treatments will be required with further studies needed to eluci-
date the underlying mechanism of VH from a transdiagnostic 
perspective and the role of dysfunctional distributed brain 
networks. Clinical trials for non- pharmacological approaches 
are also required, in particular the role of psychological ther-
apies such as rescripting, imagery transformation, desensitisa-
tion, cognitive behavioural therapy targeting patient- carer dyads 
and non- invasive brain stimulation. Both medication and non- 
pharmacological trials might target longer- term susceptibility or 
transient changes, either separately or in combination.
CoNClusIoNs
Although the clinical importance of VH and related symptoms 
has long been recognised, the evidence- base for their pathophys-
iology or treatment is limited and focusses on single conditions. 
A wider perspective is required, highlighting key similarities 
and differences between conditions and taking into account 
brain changes conferring susceptibility to such symptoms as 
well as those coincident with their occurrence. In advance of 
such developments, the workgroup concluded that treatment of 
VH, irrespective of their clinical context, would benefit from 
a common management framework and shared priorities for 
future research.
Additional references are present in online supplementary file 
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